These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36648561)

  • 1. Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis.
    Saidha S; Bell J; Harold S; Belisario JM; Hawe E; Shao Q; Wyse K; Maiese EM
    Neurol Sci; 2023 May; 44(5):1515-1532. PubMed ID: 36648561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
    Samjoo IA; Klotz L; Giovannoni G; Drudge C; Haltner A; Worthington E; Zhao M; Brennan R; Häring DA; Cameron C; Adlard N
    Mult Scler Relat Disord; 2022 Oct; 66():104031. PubMed ID: 35841716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
    Hauser SL; Cross AH; Winthrop K; Wiendl H; Nicholas J; Meuth SG; Giacomini PS; Saccà F; Mancione L; Zielman R; Bagger M; Das Gupta A; Häring DA; Jehl V; Kieseier BC; Pingili R; Stoneman D; Su W; Willi R; Kappos L
    Mult Scler; 2022 Sep; 28(10):1576-1590. PubMed ID: 35229668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders.
    Kaegi C; Wuest B; Crowley C; Boyman O
    Front Immunol; 2021; 12():788830. PubMed ID: 35185862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
    McCool R; Wilson K; Arber M; Fleetwood K; Toupin S; Thom H; Bennett I; Edwards S
    Mult Scler Relat Disord; 2019 Apr; 29():55-61. PubMed ID: 30677733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Śladowska K; Kawalec P; Holko P; Osiecka O
    Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.
    Frisch ES; Pretzsch R; Weber MS
    Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis.
    Kang C; Blair HA
    Drugs; 2022 Jan; 82(1):55-62. PubMed ID: 34897575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocrelizumab for the treatment of multiple sclerosis.
    Bigaut K; De Seze J; Collongues N
    Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review.
    Montalban X; Matthews PM; Simpson A; Petrie JL; Sammon C; Ramagopalan S; Disanto G; Kuhle J
    Ann Clin Transl Neurol; 2023 Mar; 10(3):302-311. PubMed ID: 36728340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
    Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
    Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
    Hauser SL; Kappos L; Bar-Or A; Wiendl H; Paling D; Williams M; Gold R; Chan A; Milo R; Das Gupta A; Karlsson G; Sullivan R; Graham G; Merschhemke M; Häring DA; Vermersch P
    Neurol Ther; 2023 Oct; 12(5):1491-1515. PubMed ID: 37450172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy and Safety of Anti-CD20 Antibody Treatments in Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-analysis.
    Wu X; Tan X; Zhang J; Wang Z; Wu W; Wang S; Liu Y; Wang Z
    CNS Drugs; 2022 Nov; 36(11):1155-1170. PubMed ID: 36245023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain.
    Vudumula U; Patidar M; Gudala K; Karpf E; Adlard N
    J Med Econ; 2023; 26(1):11-18. PubMed ID: 36472139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study.
    Pontieri L; Blinkenberg M; Bramow S; Papp V; Rasmussen PV; Kant M; Schäfer J; Mathiesen HK; Jensen MB; Sirakov G; Berg JM; Kopp TI; Joensen H; Sellebjerg F; Magyari M
    Eur J Neurol; 2022 Feb; 29(2):496-504. PubMed ID: 34644452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
    Hauser SL; Zielman R; Das Gupta A; Xi J; Stoneman D; Karlsson G; Robertson D; Cohen JA; Kappos L
    Mult Scler; 2023 Oct; 29(11-12):1452-1464. PubMed ID: 37691530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
    Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
    Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ofatumumab for relapsing forms of multiple sclerosis.
    Gajofatto A; Orlandi R
    Drugs Today (Barc); 2022 Jan; 58(1):9-21. PubMed ID: 35107090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis.
    Cotchett KR; Dittel BN; Obeidat AZ
    Mult Scler Relat Disord; 2021 Apr; 49():102787. PubMed ID: 33516134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab.
    Habek M; Piskač D; Gabelić T; Barun B; Adamec I; Krbot Skorić M
    Mult Scler Relat Disord; 2022 Jun; 62():103798. PubMed ID: 35429819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.